• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LIU Mingxia,HAN Fengsheng,LIU Yanzhen,SUN Yunbei.Progress and safety characteristics in thrombopoietin receptor agonists against immune thrombocytopenia[J].Journal Of Pharmaceutical Research,2024,43(2):184-188,193[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2972times   Download 2711次 QR Code for this article
Scan with your phone!
血小板生成素受体激动剂研发进展及安全性特征
刘明霞1,韩风生2,刘延珍2,孙运贝2
Font:Larger+|Default|Smaller-
(1.山东大学,山东 济南 250012;2.山东罗欣药业集团股份有限公司,山东 临沂 276017)
摘要:
原发性免疫性血小板减少症(ITP)是一种免疫介导的出血性疾病,其特征是血小板计数减少和出血风险增加。传统的ITP治疗策略可通过减轻免疫介导的血小板破坏发挥治疗作用,如糖皮质激素、免疫球蛋白、免疫调节剂或脾切除术等。但许多患者对这些疗法响应性差,且与治疗相关的副作用和禁忌症也限制了其使用。近年来,促血小板生成素受体激动剂(TPO-RA),成为ITP 治疗新的选择。本文着重讨论TPO-RA的研发进展及安全性特征,旨在为TPO-RA的研发和临床用药提供参考。
关键词:  免疫性血小板减少症  血小板生成素受体激动剂  安全性特征  研发进展
DOI:10.13506/j.cnki.jpr.2024.02.014
基金项目:
Progress and safety characteristics in thrombopoietin receptor agonists against immune thrombocytopenia
LIU Mingxia1,HAN Fengsheng2,LIU Yanzhen2,SUN Yunbei2
(1. Shandong University, Jinan 250012,China;2.Shandong Luoxin Pharmaceutical Group Co., Ltd.,Linyi 276017,China)
Abstract:
Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Traditional ITP treatment strategies work through mitigating immune-mediated platelet destruction,such as glucocorticosteroids, immunoglobulins, immunomodulatory agents, or splenectomy. Although these strategies are usually effective, many patients have poor responsiveness to these therapies and their use is limited by treatment-related side effects and contraindications.In recent years, thrombopoietin receptor agonists (TPO-RA) ,by promoting platelet production,has become a new choice for the treatment of ITP. This article focuses on the progress and safety characteristics of TPO-RA, aiming to provide reference for the research and clinical use of TPO-RA.
Key words:  Primary immune thrombocytopenia  Thrombopoietin receptor agonists  Safety characteristics  Research and development progress
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.